NCBI Taxonomy: 146922
Streptomyces griseofuscus (ncbi_taxid: 146922)
found 79 associated metabolites at species taxonomy rank level.
Ancestor: Streptomyces
Child Taxonomies: none taxonomy data.
Physostigmine
Physostigmine is a white, odorless, microcrystalline powder. Used as a cholinergic (anticholinesterase) agent and as a veterinary medication. (EPA, 1998) Physostigmine is a carbamate ester and an indole alkaloid. It has a role as a miotic, an EC 3.1.1.8 (cholinesterase) inhibitor and an antidote to curare poisoning. A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. Physostigmine is a natural product found in Streptomyces griseofuscus, Streptomyces, and other organisms with data available. A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. See also: Physostigmine Salicylate (active moiety of). A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. [PubChem] S - Sensory organs > S01 - Ophthalmologicals > S01E - Antiglaucoma preparations and miotics > S01EB - Parasympathomimetics V - Various > V03 - All other therapeutic products > V03A - All other therapeutic products > V03AB - Antidotes D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D002800 - Cholinesterase Inhibitors D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D008916 - Miotics C471 - Enzyme Inhibitor > C47792 - Acetylcholinesterase Inhibitor D004791 - Enzyme Inhibitors KEIO_ID E007; [MS2] KO008958 KEIO_ID E007
INDANOMYCIN
C31H43NO4 (493.31919180000006)
An indene that is (3aS,7aR)-2,3,3a,4,5,7a-hexahydro-1H-indene which is substituted at the 2-pro-R position by a 1H-pyrrol-2-ylcarbonyl group, at the 9-pro-S position by an ethyl group, and at the 5-pro-R position by a hexa-1,3-dineyl group in which position 4 has been substituted by a (2R,3S,6R)-6-[(1R)-1-carboxyethyl]-3-methyltetrahydropyran-2-yl group. It exhibits activity against Gram-positive bacteria as well as antihypertensive and antitumour. It also functions as an effective growth promoter for ruminants.
Physostigmine
CONFIDENCE standard compound; INTERNAL_ID 979; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5547; ORIGINAL_PRECURSOR_SCAN_NO 5545 S - Sensory organs > S01 - Ophthalmologicals > S01E - Antiglaucoma preparations and miotics > S01EB - Parasympathomimetics V - Various > V03 - All other therapeutic products > V03A - All other therapeutic products > V03AB - Antidotes D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D002800 - Cholinesterase Inhibitors D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D008916 - Miotics C471 - Enzyme Inhibitor > C47792 - Acetylcholinesterase Inhibitor D004791 - Enzyme Inhibitors CONFIDENCE standard compound; INTERNAL_ID 979; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5557; ORIGINAL_PRECURSOR_SCAN_NO 5556 CONFIDENCE standard compound; INTERNAL_ID 979; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5565; ORIGINAL_PRECURSOR_SCAN_NO 5563 CONFIDENCE standard compound; INTERNAL_ID 979; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5582; ORIGINAL_PRECURSOR_SCAN_NO 5581 CONFIDENCE standard compound; INTERNAL_ID 979; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5563; ORIGINAL_PRECURSOR_SCAN_NO 5562 CONFIDENCE standard compound; INTERNAL_ID 979; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5574; ORIGINAL_PRECURSOR_SCAN_NO 5571 Formula(Parent): C15H21N3O2; Bottle Name:Eserine; PRIME Parent Name:Eserine / Physostigmine; PRIME in-house No.:V0352 0226; SubCategory_DNP: Alkaloids derived from tryptophan, Simple tryptamine alkaloids, Indole alkaloids Annotation level-1
(2s)-2-amino-n-[(2s,4r,5r)-5-[6-(dimethylamino)purin-9-yl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-3-(4-methoxyphenyl)propanimidic acid
C22H29N7O5 (471.22300640000003)
(2r)-2-[(5s,6r)-6-[(3e,5e)-6-[(1s,4s,5r)-1-ethyl-4-(1h-pyrrole-2-carbonyl)-2,3,3a,4,5,7a-hexahydro-1h-inden-5-yl]hexa-3,5-dien-3-yl]-5-methyloxan-2-yl]propanoic acid
C31H43NO4 (493.31919180000006)
n-{[(2e,3r,4r,5s)-3-(acetyloxy)-4-hydroxy-1-azabicyclo[3.1.0]hexan-2-ylidene][(2-oxopropyl)-c-hydroxycarbonimidoyl]methyl}-2-(3-methoxy-5-methylnaphthalene-1-carbonyloxy)-2-(2-methyloxiran-2-yl)ethanimidic acid
C30H33N3O10 (595.2165838000001)
n-{[(2e)-3-(acetyloxy)-4-hydroxy-1-azabicyclo[3.1.0]hexan-2-ylidene][(e)-[(1e)-1-hydroxy-3-oxobut-1-en-2-yl]-c-hydroxycarbonimidoyl]methyl}-2-[(e,e)-3-methoxy-5-methylnaphthalene-1-carbonyloxy]-2-(2-methyloxiran-2-yl)ethanimidic acid
C31H33N3O11 (623.2114988000001)
2-(3-methoxy-5-methylnaphthalene-1-carbonyloxy)-2-(2-methyloxiran-2-yl)ethanimidic acid
2-[(2e,3r,4r,5s)-3-(acetyloxy)-4-hydroxy-1-azabicyclo[3.1.0]hexan-2-ylidene]-2-{[(2s)-1-hydroxy-2-(3-methoxy-5-methylnaphthalene-1-carbonyloxy)-2-[(2s)-2-methyloxiran-2-yl]ethylidene]amino}-n-(2-oxopropyl)ethanimidic acid
C30H33N3O10 (595.2165838000001)
(2s)-2-amino-n-[(2s,3s,4r,5r)-5-[6-(dimethylamino)purin-9-yl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-3-(4-methoxyphenyl)propanimidic acid
C22H29N7O5 (471.22300640000003)
1-{[(3as,8ar)-1,3a,8-trimethyl-2h,3h,8ah-pyrrolo[2,3-b]indol-5-yl]oxy}-n-methylmethanimidic acid
(2s)-2-[(2s,5r,6s)-6-[(3e,5e)-6-[(1r,3as,4r,5s,7ar)-1-ethyl-4-(1h-pyrrole-2-carbonyl)-2,3,3a,4,5,7a-hexahydro-1h-inden-5-yl]hexa-3,5-dien-3-yl]-5-methyloxan-2-yl]propanoic acid
C31H43NO4 (493.31919180000006)
(e)-2-[(2e,3r,4r)-3-(acetyloxy)-4-hydroxy-1-azabicyclo[3.1.0]hexan-2-ylidene]-2-{[(2s)-1-hydroxy-2-[(e,e)-3-methoxy-5-methylnaphthalene-1-carbonyloxy]-2-[(2s)-2-methyloxiran-2-yl]ethylidene]amino}-n-[(1e)-1-hydroxy-3-oxobut-1-en-2-yl]ethanimidic acid
C31H33N3O11 (623.2114988000001)
1-[(4s)-4-amino-4-carboxylatobutyl]-4-(c-hydroxycarbonimidoyl)pyridazin-1-ium
2-(6-{6-[1-ethyl-4-(1h-pyrrole-2-carbonyl)-2,3,3a,4,5,7a-hexahydro-1h-inden-5-yl]hexa-3,5-dien-3-yl}-5-methyloxan-2-yl)propanoic acid
C31H43NO4 (493.31919180000006)
(2s)-2-amino-5-[4-(c-hydroxycarbonimidoyl)-1,2-diazinan-1-yl]pentanoic acid
(z)-2-[(2e,3r,4r,5s)-3-(acetyloxy)-4-hydroxy-1-azabicyclo[3.1.0]hexan-2-ylidene]-2-{[(2s)-1-hydroxy-2-[(z,z)-3-methoxy-5-methylnaphthalene-1-carbonyloxy]-2-[(2s)-2-methyloxiran-2-yl]ethylidene]amino}-n-[(1z)-1-hydroxy-3-oxobut-1-en-2-yl]ethanimidic acid
C31H33N3O11 (623.2114988000001)
(2r)-2-[(5s,6r)-6-[(3e,5e)-6-[(1s,3ar,4s,5r,7as)-1-ethyl-4-(1h-pyrrole-2-carbonyl)-2,3,3a,4,5,7a-hexahydro-1h-inden-5-yl]hexa-3,5-dien-3-yl]-5-methyloxan-2-yl]propanoic acid
C31H43NO4 (493.31919180000006)
3-methoxy-5-methylnaphthalene-1-carboximidic acid
C13H13NO2 (215.09462380000002)